2.06 0.00 (0.00%)
After hours: 6:26PM EDT
|Bid||2.05 x 3000|
|Ask||2.10 x 29200|
|Day's Range||1.93 - 2.07|
|52 Week Range||1.55 - 6.19|
|Beta (3Y Monthly)||2.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer - AGEN PD-1 & CTLA-4 (AGEN1884) is the most advanced combination in 2L cervical cancer LEXINGTON, ...
NEW YORK, Oct. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
LEXINGTON, Mass., Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the 2018 Cantor Fitzgerald Global Healthcare Conference at the Intercontinental NY Barclay Hotel.
LEXINGTON, Mass., Sept. 21, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation (XOMA), where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck. Agenus received $15.0 million at closing and retains the majority (67%) of all future royalties and 90% of all milestones from Incyte and Merck.
Anyone researching Agenus Inc (NASDAQ:AGEN) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...
LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Based on this milestone and under the terms of the agreement, Agenus received a $5 million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte. "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
- Both TCRs discovered by Novel "T-Rx™" Discovery Platform LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing ...
LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies ...
Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper
LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck. "We continue to deliver on all milestones with our existing partners." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Agenus (AGEN) delivered earnings and revenue surprises of 36.84% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 24 cents. The company's shares closed at $1.75. A year ago, they were trading at $3.85. _____ This story was generated ...
- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. ...